Drug combination versus surgery for early kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether two drugs (Anlotinib and Benmelstobart) can shrink early-stage kidney tumors instead of surgery. It may help patients avoid or delay surgery if the drugs work well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Good overall health (able to care for yourself with minimal help from doctors)
- Newly diagnosed early-stage kidney cancer (cT1b stage) scheduled for partial kidney removal
- At least one tumor that can be measured on imaging scans
- No prior cancer drugs, immunotherapy, or experimental treatments for kidney cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
This trial tests whether combining focused radiation (SBRT) with anlotinib and bimepolizumab can shrink or slow kidney cancer that has spread and cannot be surgically removed. It's designed for people with a specific type of kidney cancer who are generally healthy enough to handle these treatments.
This trial tests giving two medications (a PD-L1 inhibitor and anlotinib) before surgery for complex kidney cancer, to try to shrink the tumor enough that surgeons can remove just part of the kidney instead of the whole organ. The goal is to preserve kidney function and avoid dialysis.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.